Skip to content
  • Home
  • About
  • Contact
  • Services
  • Advertise with Us
US Pharma Marketing Logo

US Pharma Marketing

  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A

Author: Jayshree Gondane

Jayshree Gondane, BHMS student and healthcare enthusiast with a genuine interest in medical sciences, patient well-being, and the real-world workings of the healthcare system.
How Digital Marketing Can Fix Clinical Trial Recruitment Problems
Posted in
  • Digital Transformation
  • Strategy & Execution

How Digital Marketing Can Fix Clinical Trial Recruitment Problems

Clinical trial recruitment in the United States is under structural pressure. Despite record research and development … How Digital Marketing Can Fix Clinical Trial Recruitment ProblemsRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
Why Pharma Companies Struggle With Trial Participant Retention
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Pharma Companies Struggle With Trial Participant Retention

Nearly 30 percent of clinical trial participants withdraw before study completion in certain therapeutic areas, according … Why Pharma Companies Struggle With Trial Participant RetentionRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
The Role of Marketing in Accelerating Clinical Trial Enrollment
Posted in
  • Digital Transformation
  • Strategy & Execution

The Role of Marketing in Accelerating Clinical Trial Enrollment

A pivotal oncology trial enrolling 600 patients across 80 U.S. sites can burn through millions of … The Role of Marketing in Accelerating Clinical Trial EnrollmentRead more

by Jayshree Gondane•February 13, 2026February 13, 2026•0
Why U.S. Clinical Trial Timelines Keep Getting Longer
Posted in
  • Industry Landscape
  • Regulatory Compliance

Why U.S. Clinical Trial Timelines Keep Getting Longer

The average time required to bring a new medicine from discovery to approval in the United … Why U.S. Clinical Trial Timelines Keep Getting LongerRead more

by Jayshree Gondane•February 13, 2026February 13, 2026•0
How Lack of Patient-Centricity Hurts Clinical Trial Outcomes
Posted in
  • Strategy & Execution

How Lack of Patient-Centricity Hurts Clinical Trial Outcomes

In 2023, the FDA’s Center for Drug Evaluation and Research approved 55 novel drugs, continuing a … How Lack of Patient-Centricity Hurts Clinical Trial OutcomesRead more

by Jayshree Gondane•February 12, 2026February 12, 2026•0
Top Clinical Trial Challenges No One in Pharma Talks About
Posted in
  • Case Studies & Trends
  • Strategy & Execution

Top Clinical Trial Challenges No One in Pharma Talks About

The U.S. pharmaceutical industry invests heavily in marketing, with estimates from Statista showing that spending on … Top Clinical Trial Challenges No One in Pharma Talks AboutRead more

by Jayshree Gondane•February 12, 2026February 12, 2026•0
The Biggest Reasons Clinical Trials Fail to Scale
Posted in
  • Case Studies & Trends
  • Industry Landscape

The Biggest Reasons Clinical Trials Fail to Scale

Clinical trials are the cornerstone of pharmaceutical innovation, providing the evidence necessary to bring safe and … The Biggest Reasons Clinical Trials Fail to ScaleRead more

by Jayshree Gondane•February 10, 2026February 10, 2026•0
Why Many Biotech Startups Never Make It Past Early Trials
Posted in
  • Case Studies & Trends
  • Industry Landscape

Why Many Biotech Startups Never Make It Past Early Trials

Over 90% of biotech startups never advance beyond early clinical trials, a statistic that underscores the … Why Many Biotech Startups Never Make It Past Early TrialsRead more

by Jayshree Gondane•February 10, 2026February 11, 2026•0
How Poor Trial Design Increases Drug Development Costs
Posted in
  • Case Studies & Trends
  • Regulatory Compliance

How Poor Trial Design Increases Drug Development Costs

In pharmaceutical development, clinical trials serve as the backbone of bringing a new therapy from concept … How Poor Trial Design Increases Drug Development CostsRead more

by Jayshree Gondane•February 10, 2026February 10, 2026•0
Why Phase II Clinical Trials Are the Graveyard of Drug Development
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Phase II Clinical Trials Are the Graveyard of Drug Development

Nearly 60 percent of drug candidates that enter Phase II clinical trials never advance to Phase … Why Phase II Clinical Trials Are the Graveyard of Drug DevelopmentRead more

by Jayshree Gondane•February 8, 2026February 8, 2026•0

Posts pagination

Previous 1 … 8 9 10 … 20 Next

Recent Posts

  • The Silent Architects: How Private Equity Is Rewriting the Rules of Pharmaceutical Commercialization
  • Location Is the New Targeting: How Geofencing Is Changing Who Gets Diagnosed and Treated
  • When a Drug Loses Its Patent, Marketing Becomes Defense, Not Growth
  • The Hidden Compliance Risk of AI in Pharmaceutical Promotion
  • The Truth About Drug Price Transparency Laws and Pharmaceutical Marketing Strategy

Recent Comments

No comments to show.
Copyright © 2026 US Pharma Marketing.
Powered by WordPress and HybridMag.
  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A